NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹1,026 Cr | ₹880 Cr | ₹793 Cr | ₹739 Cr | ₹157 Cr |
What is the latest Total Liabilities ratio of NATH BIOGENES (INDIA) ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹1,026 Cr |
| Mar2024 | ₹880 Cr |
| Mar2023 | ₹793 Cr |
| Mar2022 | ₹739 Cr |
| Mar2013 | ₹157 Cr |
How is Total Liabilities of NATH BIOGENES (INDIA) Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,026 Cr | 16.58 | |
| Mar2024 | ₹880 Cr | 11.03 | |
| Mar2023 | ₹793 Cr | 7.21 | |
| Mar2022 | ₹739 Cr | 369.87 | |
| Mar2013 | ₹157 Cr | - | |
Compare Total Liabilities of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹319.4 Cr | 10.2% | 17.9% | 11.2% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹10,668.5 Cr | 2.7% | 0.3% | -16.3% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,755.5 Cr | -0.1% | 14.1% | -32.8% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,238.8 Cr | 8.9% | 31% | -6.2% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,052.8 Cr | 1.9% | 22.3% | -12.9% | Stock Analytics | |
| INDO US BIOTECH | ₹216.6 Cr | 0.8% | 8.9% | -32.3% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | 10.2% |
17.9% |
11.2% |
| SENSEX | 2.4% |
3.2% |
5.8% |
You may also like the below Video Courses